Long-form, evidence-first breakdowns — training, nutrition, recovery, and research literacy. Every claim traced to the paper it came from.
COMPOUNDS · ERR AGONISTSTwo experimental "exercise mimetic" molecules, one family, one question: which is better? The usual split says 332 for fat and 915 for endurance. The mouse data says endurance is a tie, the fat comparison was never run, and the real difference is that one works by mouth and the other doesn't. Neither has a single human data point. Includes an interactive potency chart.
Read the article → DRUGS · BLOODWORKA November 2026 reel claimed SGLT2 inhibitors raise hematocrit via EPO, pointing to a 70,000-person meta-analysis. The meta-analysis is real and peer-reviewed. The claim is mostly right, the mechanism is half right — and the part that matters most is whether the rise is dangerous. Includes a stacking projector for SGLT2 inhibitor plus testosterone.
Read the article → POLICY · PEPTIDESOn October 28, 2026, HHS filed a policy letting pharmacies compound six unapproved peptides without fear of FDA enforcement. The science didn't change. The enforcement posture did. The six peptides, the one left out, the three distinctions that carry the story — and what still hasn't been answered.
Read the article → MYOSTATIN · MUSCLE BIOLOGYA September 2026 study grew dramatically bigger muscles in diseased mice — and the muscles didn't get any stronger. Mass went up, force didn't, and the growth vanished weeks after treatment stopped. What the experiment actually proves, what it doesn't, and why the field's new standard is contractile performance, not bulk.
Read the article → HYPERTROPHY · TRAININGMore sets grow more muscle — on average. But the curve bends hard, every set charges fatigue, and the "optimal" number depends on the lifter. The full evidence review: dose-response data, proximity to failure, frequency, individual variability, and a practical decision flowchart.
Read the article →